GLUE PE Ratio & Valuation,Is GLUE Overvalued

GLUE Relative Valuation

GLUE's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, GLUE is overvalued; if below, it's undervalued.

Historical Valuation

Monte Rosa Therapeutics Inc (GLUE) is now in the Overvalued zone, suggesting that its current forward PS ratio of 31.42 is considered Overvalued compared with the five-year average of -4.74. The fair price of Monte Rosa Therapeutics Inc (GLUE) is between 2.93 to 9.33 according to relative valuation methord. Compared to the current price of 16.31 USD , Monte Rosa Therapeutics Inc is Overvalued By 74.76%.

Relative Value

Fair Zone

2.93-9.33

Current Price：16.31

74.76%

Overvalued

-9.48

0.00

EV/EBITDA

Monte Rosa Therapeutics Inc. (GLUE) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -2.23. The thresholds are as follows: Strongly Undervalued below -9.72, Undervalued between -9.72 and -5.98, Fairly Valued between 1.51 and -5.98, Overvalued between 1.51 and 5.25, and Strongly Overvalued above 5.25. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.

-4.50

EV/EBIT

Monte Rosa Therapeutics Inc. (GLUE) has a current EV/EBIT of -4.50. The 5-year average EV/EBIT is -2.21. The thresholds are as follows: Strongly Undervalued below -8.83, Undervalued between -8.83 and -5.52, Fairly Valued between 1.10 and -5.52, Overvalued between 1.10 and 4.41, and Strongly Overvalued above 4.41. The current Forward EV/EBIT of -4.50 falls within the Historic Trend Line -Fairly Valued range.

31.42

Monte Rosa Therapeutics Inc. (GLUE) has a current PS of 31.42. The 5-year average PS is 10.06. The thresholds are as follows: Strongly Undervalued below -15.77, Undervalued between -15.77 and -2.85, Fairly Valued between 22.98 and -2.85, Overvalued between 22.98 and 35.89, and Strongly Overvalued above 35.89. The current Forward PS of 31.42 falls within the Overvalued range.

-7.27

P/OCF

Monte Rosa Therapeutics Inc. (GLUE) has a current P/OCF of -7.27. The 5-year average P/OCF is -4.96. The thresholds are as follows: Strongly Undervalued below -12.48, Undervalued between -12.48 and -8.72, Fairly Valued between -1.19 and -8.72, Overvalued between -1.19 and 2.57, and Strongly Overvalued above 2.57. The current Forward P/OCF of -7.27 falls within the Historic Trend Line -Fairly Valued range.

42.06

P/FCF

Monte Rosa Therapeutics Inc. (GLUE) has a current P/FCF of 42.06. The 5-year average P/FCF is -2.10. The thresholds are as follows: Strongly Undervalued below -36.88, Undervalued between -36.88 and -19.49, Fairly Valued between 15.30 and -19.49, Overvalued between 15.30 and 32.69, and Strongly Overvalued above 32.69. The current Forward P/FCF of 42.06 falls within the Strongly Overvalued range.

Monte Rosa Therapeutics Inc (GLUE) has a current Price-to-Book (P/B) ratio of 4.10. Compared to its 3-year average P/B ratio of 1.59 , the current P/B ratio is approximately 157.95% higher. Relative to its 5-year average P/B ratio of 1.75, the current P/B ratio is about 134.63% higher. Monte Rosa Therapeutics Inc (GLUE) has a Forward Free Cash Flow (FCF) yield of approximately 13.65%. Compared to its 3-year average FCF yield of -19.74%, the current FCF yield is approximately -169.16% lower. Relative to its 5-year average FCF yield of -17.72% , the current FCF yield is about -177.07% lower.

4.10

P/B

Median3y

1.59

Median5y

1.75

13.65

FCF Yield

Median3y

-19.74

Median5y

-17.72

Competitors Valuation Multiple

The average P/S ratio for GLUE's competitors is 13.74, providing a benchmark for relative valuation. Monte Rosa Therapeutics Inc Corp (GLUE) exhibits a P/S ratio of 31.42, which is 128.58% above the industry average. Given its robust revenue growth of 38.54%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of GLUE increased by 135.01% over the past 1 year. The primary factor behind the change was an increase in P/E Change from 30.13 to 64.63.

The secondary factor is the Revenue Growth, contributed 38.54%to the performance.

Overall, the performance of GLUE in the past 1 year is driven by P/E Change. Which is more unsustainable.

38.54%

9.22M → 12.77M

Revenue Growth

-18.07%

-258.89 → -212.10

Margin Expansion

114.54%

30.13 → 64.63

P/E Change

135.01%

6.94 → 16.31

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is Monte Rosa Therapeutics Inc (GLUE) currently overvalued or undervalued?

What is Monte Rosa Therapeutics Inc (GLUE) fair value?

GLUE's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Monte Rosa Therapeutics Inc (GLUE) is between 2.93 to 9.33 according to relative valuation methord.

How does GLUE's valuation metrics compare to the industry average?

What is the current P/B ratio for Monte Rosa Therapeutics Inc (GLUE) as of Dec 15 2025?

As of Dec 15 2025, Monte Rosa Therapeutics Inc (GLUE) has a P/B ratio of 4.10. This indicates that the market values GLUE at 4.10 times its book value.

What is the current FCF Yield for Monte Rosa Therapeutics Inc (GLUE) as of Dec 15 2025?

As of Dec 15 2025, Monte Rosa Therapeutics Inc (GLUE) has a FCF Yield of 13.65%. This means that for every dollar of Monte Rosa Therapeutics Inc’s market capitalization, the company generates 13.65 cents in free cash flow.

What is the current Forward P/E ratio for Monte Rosa Therapeutics Inc (GLUE) as of Dec 15 2025?

As of Dec 15 2025, Monte Rosa Therapeutics Inc (GLUE) has a Forward P/E ratio of -9.48. This means the market is willing to pay $-9.48 for every dollar of Monte Rosa Therapeutics Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Monte Rosa Therapeutics Inc (GLUE) as of Dec 15 2025?

As of Dec 15 2025, Monte Rosa Therapeutics Inc (GLUE) has a Forward P/S ratio of 31.42. This means the market is valuing GLUE at $31.42 for every dollar of expected revenue over the next 12 months.

GLUE Valuation